Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report

BMC Cancer
Chung Young KimSang In Khwarg

Abstract

Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid. A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relie...Continue Reading

References

Jul 25, 2003·Ophthalmic Plastic and Reconstructive Surgery·Bita EsmaeliVictor G Prieto
Jan 1, 1962·The British Journal of Ophthalmology·Y Dayal
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael UntchGunter von Minckwitz
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian E KropHoward A Burris
Oct 21, 2010·Orbit·Ludwig M HeindlLeonard M Holbach
Dec 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard A BurrisJoyce A O'Shaughnessy
Oct 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LoRussoMark X Sliwkowski
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Jul 19, 2016·Ophthalmic Plastic and Reconstructive Surgery·Constanza MansurBita Esmaeli
Aug 2, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Hao ChenWei Li
Nov 14, 2016·American Journal of Ophthalmology Case Reports·In Ah ParkKyung-Ja Cho
Apr 5, 2018·Clinical Breast Cancer·Elke O KrepsHannelore Denys

❮ Previous
Next ❯

Citations

Apr 1, 2021·Drugs·Blake H FortesLauren A Dalvin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.